yahoo_financeOriginal article
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Data ReadoutpositiveVabysmoPositive
AI Analysis
Summary
Roche announced that Vabysmo demonstrated sustained two-year clinical results in difficult-to-treat neovascular age-related macular degeneration, supporting its continued efficacy in this patient population.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Sustained two-year results demonstrated in difficult-to-treat form of nAMD
Importance:6/10
Sentiment:
0.75
ophthalmologyage-related macular degenerationclinical datatwo-year results
Related Companies
Read the original article
Published by yahoo_finance on August 28, 2026 7:00 AM